---
title: Post-exposure Influenza Prophylaxis in a Hospital Setting
nct_id: NCT07496736
overall_status: ACTIVE_NOT_RECRUITING
phase: PHASE3
sponsor: University Medical Centre Ljubljana
study_type: INTERVENTIONAL
primary_condition: Influenza
countries: Slovenia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07496736.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07496736"
ct_last_update_post_date: 2026-04-30
last_seen_at: "2026-05-12T06:33:32.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Post-exposure Influenza Prophylaxis in a Hospital Setting

**Official Title:** Post-Exposure Influenza Chemoprophylaxis With Oseltamivir for Five Days vs Ten Days in Acute-Care Hospital: a Non-Inferiority Randomized Open-Label Study

**NCT ID:** [NCT07496736](https://clinicaltrials.gov/study/NCT07496736)

## Key Facts

- **Status:** ACTIVE_NOT_RECRUITING
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** University Medical Centre Ljubljana
- **Conditions:** Influenza
- **Start Date:** 2025-12-01
- **Completion Date:** 2028-03-31
- **CT.gov Last Update:** 2026-04-30

## Brief Summary

The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza in a hospital setting.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 18 years or older
* exposure to influenza during hospitalization
* risk factors for influenza complications
* consent for participation obtained

Exclusion Criteria:

* younger than 18 years
* hematological malignancy
* hospitalized in intensive care unit
* refusal to participate
```

## Arms

- **oseltamivir 5 days** (ACTIVE_COMPARATOR) — post-exposure influenza prophylaxis with oseltamivir for 5 days
- **oseltamivir 10 days** (ACTIVE_COMPARATOR) — post-exposure influenza prophylaxis with oseltamivir for 10 days

## Interventions

- **Oseltamivir** (DRUG) — oseltamivir 5 days
- **Oseltamivir** (DRUG) — oseltamivir 10 days

## Primary Outcomes

- **frequency of influenza** _(time frame: 10 days after completing prophylaxis)_

## Locations (1)

- University Medical Centre Ljubljana, Ljubljana, Slovenia

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university medical centre ljubljana|ljubljana||slovenia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07496736.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07496736*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*